US Foreign Aid

Showing 11216 articles
Business

Novo Nordisk's Stock Slump: A Buying Opportunity or a Sign of Deeper Trouble?

Shares of the Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) have retreated sharply, down 14% in a month and 44% over the past year. With the stock closing at $47.19, a significant gap has emerged between its market price and some fair value estimates near $95, prompting investors to reassess the company's prospects amid evolving competition in its key GLP-1 drug market.